Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laflunimus SCHEMBL9234178 | 1.00 | DHODH (0.67) | DHODHLMNAKDRBRAFUSP30 | |
| Laflunimus SCHEMBL29677348 | 1.00 | DHODH (0.67) | DHODHLMNAKDRBRAFUSP30 | |
| Laflunimus SCHEMBL22908 | 1.00 | DHODH (0.67) | DHODHLMNAKDRBRAFUSP30 | |
| SCHEMBL17100730 | 0.86 | DHODH (0.49) | DHODHKDRBRAFUSP30EPHX2 | |
| SCHEMBL21539519 | 0.86 | DHODH (0.49) | DHODHKDRBRAFUSP30EPHX2 | |
| SCHEMBL15196662 | 0.86 | DHODH (0.62) | DHODHLMNAGAATP53MAPT | |
| SCHEMBL8717137 | 0.84 | DHODH (0.66) | DHODHLMNAGAATHRB | |
| SCHEMBL8717143 | 0.84 | DHODH (0.66) | DHODHLMNAGAATHRB | |
| SCHEMBL16274172 | 0.82 | DHODH (0.58) | DHODHGAATP53MAPTTHRB | |
| SCHEMBL28236310 | 0.81 | DHODH (0.49) | DHODHLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928772-B1 | NANOPARTICULATE COMPOSITION | ALGIAX PHARMACEUTICALS GMBH (DE) | 2024-06-19 | — | — | EP | claimed |
| EP-2632451-B1 | USE OF MALONONITRILAMIDES IN NEUROPATHIC PAIN | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| CN-103179962-B | Use of malononitrilamides in neuropathic pain | 艾格埃克斯制药有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9468615-B2 | Use of malononitrilamides in neuropathic pain | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| EP-2608782-B1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8957098-B2 | Use of leflunomide and malononitrilamides | ALGIAX PHARMACEUTICALS GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20140357722-A1 | Use of Malononitrilamides in Neuropathic Pain | ALGIAX PHARMACEUTICALS GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| WO-2013156231-A1 | USE OF IMIDAZOTRIAZINONES IN NEUROPATHIC PAIN | ALGIAX PHARMACEUTICALS GMBH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130274301-A1 | Novel Use of Leflunomide and Malononitrilamides | AL-GIAX PHARMACEUTICALS GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| EP-2632451-A2 | USE OF MALONONITRILAMIDES IN NEUROPATHIC PAIN | Algiax Pharmaceuticals GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217737-A1 | Use of Malononitrilamides in Neuropathic Pain | AL-GIAX PHARMACEUTICALS GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-2608782-A1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | Algiax Pharmaceuticals GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120208855-A1 | AMINO-BENZOIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DIHYDROGENASE-RELATED DISORDERS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| WO-2012055567-A2 | USE OF MALONONITRILAMIDES IN NEUROPATHIC PAIN | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012025217-A1 | NOVEL USE OF LEFLUNOMIDE AND MALONONITRILAMIDES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| EP-0649660-A2 | Pharmaceutical composition for parenteral, enteral and dermal administration of essentially insoluble drugs and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217737-A1 | Use of Malononitrilamides in Neuropathic Pain | PMP22, GAP43, ACHE | DHODH 896/4885LMNA 3803/4885KDR 3549/4885 |
| US-20120208855-A1 | AMINO-BENZOIC ACID DERIVATIVES FOR USE IN THE TREATMENT OF DIHYDROGENASE-RELATED DISORDERS | DHODH, ALDH7A1, DLD | DHODH 1/4885LMNA 2525/4885KDR 4567/4885 |
| US-20140357722-A1 | Use of Malononitrilamides in Neuropathic Pain | PMP22, GAP43, ACHE | DHODH 896/4885LMNA 3803/4885KDR 3549/4885 |
| US-20130274301-A1 | Novel Use of Leflunomide and Malononitrilamides | LEF1, TPMT, MALT1 | DHODH 218/4885LMNA 1598/4885KDR 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.